Why Illumina Stock Declined by 11% in January
Illumina (NASDAQ: ILMN) saw its stock decline by 11% last month, according to data from S&P Global Market Intelligence.
The move has knocked the stock down from the $300 mark, and it's still around 23% down from its peak of $378 back in July 2019, but investors should note that the stock has actually rallied hard since the start of 2017 and has more than doubled since then, and I believe Illumina still qualifies as one of the better biotech stocks to own.
Image Source: Getty Images.
Source Fool.com
